- Home
- DBL vs IKT Comparison
DBL vs IKT Comparison
Compare DBL & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | IKT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 240.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBL | IKT |
|---|---|---|
| Price | $14.26 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 69.7K | ★ 797.0K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.08 | $1.33 |
| 52 Week High | $16.01 | $2.26 |
Technical Indicators
Market Signals| Indicator | DBL | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 34.70 |
| Support Level | $14.12 | $1.43 |
| Resistance Level | $15.55 | $1.74 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 3.85 | 8.04 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.